Q1 Earnings Forecast for Zai Lab Issued By Leerink Partnrs

Zai Lab Limited (NASDAQ:ZLAB) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zai Lab in a research report issued on Thursday, February 20th. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($0.51) per share for the quarter. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Leerink Partnrs also issued estimates for Zai Lab’s Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

Zai Lab Trading Up 2.9 %

ZLAB opened at $33.91 on Monday. The company has a 50 day moving average of $27.17 and a 200 day moving average of $25.57. The company has a market cap of $3.71 billion, a PE ratio of -12.24 and a beta of 1.02. Zai Lab has a 12 month low of $13.48 and a 12 month high of $36.60.

Insider Activity

In other news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 13.88% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in Zai Lab in the 4th quarter worth $29,000. Public Employees Retirement System of Ohio lifted its position in Zai Lab by 20.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock valued at $484,000 after acquiring an additional 3,179 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Zai Lab by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after buying an additional 1,200 shares during the last quarter. Woodline Partners LP raised its holdings in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock worth $46,089,000 after buying an additional 151,835 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new position in Zai Lab in the fourth quarter worth about $7,857,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.